Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | PPID | Q08752 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14611259 | 0.89 | RIPK1 (0.44) | EPHX2ADAM17RIPK1MEN1KMT2A | |
| SCHEMBL14557708 | 0.89 | EPHX2 (0.41) | EPHX2ADAM17RIPK1PPID | |
| SCHEMBL14610825 | 0.88 | EPHX2 (0.46) | EPHX2ADAM17RIPK1MEN1KMT2A | |
| SCHEMBL14557706 | 0.86 | HRH3 (0.46) | EPHX2ADAM17RIPK1MEN1KMT2A | |
| SCHEMBL14569489 | 0.85 | EPHX2 (0.47) | EPHX2ADAM17RIPK1HPGDSMN1; SMN2 | |
| SCHEMBL20905412 | 0.82 | RIPK1 (0.59) | EPHX2ADAM17RIPK1PSMB8PPID | |
| SCHEMBL14557693 | 0.82 | KDM4E (0.41) | ADAM17RIPK1MEN1KMT2APSMB8 | |
| SCHEMBL14557714 | 0.80 | EPHX2 (0.37) | EPHX2ADAM17RIPK1PPID | |
| SCHEMBL14557723 | 0.80 | ADAM17 (0.35) | EPHX2ADAM17RIPK1PSMB8 | |
| SCHEMBL14610823 | 0.76 | EPHX2 (0.43) | EPHX2ADAM17RIPK1PPIDTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | EPHX2 3415/4885ADAM17 2204/4885RIPK1 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.